|
End-of-day quote
Korea S.E.
2026-10-16
|
5-day change | 1st Jan Change | ||
| 7,980.00 KRW | +18.57% |
|
+2.97% | -42.88% |
Company Valuation: Samik Pharmaceutical Company LTD.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 |
|---|---|
| Market Cap 1 | 128,125 |
| Change | - |
| Enterprise Value (EV) 1 | 99,073 |
| Change | - |
| P/E | -140x |
| PBR | 1.86x |
| PEG | 1x |
| Capitalization / Revenue | 2.13x |
| EV / Revenue | 1.65x |
| EV / EBITDA | 21.3x |
| EV / EBIT | 30.3x |
| EV / FCF | - |
| FCF Yield | - |
| Dividend per Share 2 | 40 |
| Rate of return | 0.29% |
| EPS 2 | -99.5 |
| Distribution rate | -40.2% |
| Net sales 1 | 60,020 |
| EBITDA 1 | 4,649 |
| EBIT 1 | 3,273 |
| Net income 1 | -754.9 |
| Net Debt 1 | -29,051 |
| Reference price 2 | 13,970.00 |
| Nbr of stocks (in thousands) | 9,171 |
| Announcement Date | 3/20/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 60.26M | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 29.05x | 6.95x | 18.39x | 2.15% | 394.1B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A014950 Stock
- Valuation Samik Pharmaceutical Company LTD.
Select your edition
All financial news and data tailored to specific country editions
